Patents by Inventor Sharat Singh

Sharat Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER PANEL FOR ASSESSMENT OF MUCOSAL HEALING
    Publication number: 20170010281
    Abstract: The present invention provides methods for predicting the likelihood of mucosal healing in an individual with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and/or monitoring the therapeutic efficiency of an anti-TNF? inhibitor drug.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 12, 2017
    Applicants: Nestec S.A., Katholieke Universiteit Leuven
    Inventors: Sharat Singh, Severine Vermeire
  • Apparatus and method for isolating leukocytes and tumor cells by filtration
    Patent number: 9535052
    Abstract: The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell lysates from recovered cells such as leukocytes and/or circulating tumor cells without substantial dilution of a therapeutic agent such as an anticancer drug.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: January 3, 2017
    Assignee: NESTEC S.A.
    Inventors: Sharat Singh, Xinjun Liu, Kelly D. Hester
  • SIGNALING PATHWAYS IN TISSUES FROM INFLAMMATORY BOWEL DISEASE PATIENTS
    Publication number: 20160356790
    Abstract: The present invention provides methods for measuring the total and/or activation levels of one or more analytes such as HER1, HER2, HER3, cMET, IGF-1R, PI3K, AKT, PRAS40, MEK, RSK, JAK1, STAT1, STAT3, TNF?, and/or anti-TNF? drug to determine whether a subject with inflammatory bowel disease (IBD) has non-inflamed and/or non-involved or inflamed and/or involved gastrointestinal tissue. The methods of the present invention can be used to evaluate mucosal healing, to diagnose, prognose, and monitor the progression of IBD, and to select and monitor the therapeutic response to IBD therapy.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 8, 2016
    Applicant: NESTEC S.A.
    Inventors: SHARAT SINGH, KATHERINE DRAKE, ANJALI JAIN, RICHARD KIRKLAND, XINJUN LIU
  • Compositions and methods for detecting allelic variants
    Patent number: 9512482
    Abstract: The present invention provides compositions, methods, and kits for discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides compositions, methods, and kits for determining the presence and/or level (e.g., quantitating) of rare (e.g., mutant) allelic variants, such as single nucleotide polymorphisms (SNPs) or nucleotide insertions or deletions, in samples comprising abundant (e.g., wild-type) allelic variants with high sensitivity and/or specificity. As such, in certain embodiments, the present invention provides a highly selective method for the detection of somatic mutations, e.g., in samples containing abundant levels of a wild-type allele compared to very low levels of a mutant allele.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: December 6, 2016
    Assignee: Nestec S.A.
    Inventors: Fred Princen, Fabiyola Selvaraj, Sharat Singh
  • Assays for the detection of anti-TNF drugs and autoantibodies
    Patent number: 9506920
    Abstract: The present invention provides assays for detecting and measuring the presence or level of anti-TNF? drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNF? drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 29, 2016
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Shui Long Wang, Linda Ohrmund
  • METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE
    Publication number: 20160334401
    Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 17, 2016
    Applicants: NESTEC S.A., UNIVERSITY HOSPITALS LEUVEN
    Inventors: STEVEN LOCKTON, MARC FERRANTE, SEVERINE VERMIERE, SHARAT SINGH
  • Methods for predicting response of triple-negative breast cancer to therapy
    Patent number: 9488654
    Abstract: The present invention provides compositions and methods for detecting the expression and/or activation levels of components of signal transduction pathways in tumor cells such as triple-negative metastatic breast tumor cells. Information on the expression and/or activation levels of components of signal transduction pathways derived from use of the present invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: July 10, 2012
    Date of Patent: November 8, 2016
    Assignee: DIATECH HOLDINGS, INC.
    Inventors: Xinjun Liu, Phillip Kim, Richard Kirkland, Tani Lee, Belen Ybarrondo, Sharat Singh
  • Methods for diagnosing irritable bowel syndrome
    Patent number: 9482672
    Abstract: The invention provides an ELISA assay for the determination of serum mast cell ?-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of ?-tryptase, histamine and/or prostaglandin E2.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: November 1, 2016
    Assignee: Nestec S.A.
    Inventors: Hua Gong, Shui Long Wang, Sharat Singh
  • POLYP RECURRENCE
    Publication number: 20160305944
    Abstract: The present invention provides assays and methods for determining an individual's risk of developing colorectal cancer (CRC) by analyzing a pre-cancerous polyp tissue sample. The present invention also provides assay and methods for selecting an anti-cancer therapeutic drug for an individual diagnosed as having early stage CRC.
    Type: Application
    Filed: February 22, 2016
    Publication date: October 20, 2016
    Applicant: NESTEC S.A.
    Inventors: SHARAT SINGH, NICHOLAS HOE, KELLY D. HESTER
  • Assays for detecting neutralizing autoantibodies to biologic therapy
    Patent number: 9465027
    Abstract: The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNF? drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: October 11, 2016
    Assignee: Nestec S.A.
    Inventors: Scott Hauenstein, Linda Ohrmund, Sharat Singh, Shui Long Wang
  • METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF COLORECTAL CANCER PATIENTS
    Publication number: 20160169898
    Abstract: The present invention provides assays and methods for predicting the survival of a subject having colorectal cancer (CRC), thereby determining whether the subject will have a good prognosis or poor prognosis. The present invention also provides assays and methods for predicting therapeutic efficacy and/or response to anti-cancer therapeutics in a subject having CRC, thereby selecting a therapeutic regimen to which the subject is likely to be responsive.
    Type: Application
    Filed: December 30, 2015
    Publication date: June 16, 2016
    Applicant: NESTEC S.A.
    Inventors: Phillip Kim, Anjali Jain, Sharat Singh
  • PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME
    Publication number: 20160139148
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 19, 2016
    Applicant: NESTEC S.A.
    Inventors: STEFAN WESTIN, FABIYOLA SELVARAJ, FRED PRINCEN, SHARAT SINGH
  • PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS
    Publication number: 20160130279
    Abstract: The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays The present invention also provides stable derivatives of various metabolites and short chain fatty acids. The derivative can be conjugated to a biomolecule such as a carrier protein and combined with an adjuvant to stimulate an immune response. The derivatives can also be conjugated to other biomolecules.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 12, 2016
    Applicant: NESTEC S.A.
    Inventors: FABIYOLA SELVARAJ, Fred Princen, Sharat Singh
  • DRUG SELECTION FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS
    Publication number: 20160123984
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Applicant: NESTEC S.A.
    Inventors: SHARAT SINGH, JEANNE HARVEY, PHILLIP KIM, XINJUN LIU, LIMIN LIU, ROBERT BARHAM, BRUCE NERI
  • Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
    Patent number: 9285369
    Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 15, 2016
    Assignee: NESTEC S.A.
    Inventors: Jeanne Harvey, Sharat Singh, Phillip Kim, Xinjun Liu, Robert Barham, Limin Liu
  • Methods and Compositions for Analyzing Proteins
    Publication number: 20160069893
    Abstract: Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide.
    Type: Application
    Filed: August 14, 2015
    Publication date: March 10, 2016
    Applicant: MONOGRAM BIOSCIENCES, INC.
    Inventors: Sharat Singh, Hossein Salimi-Moosavi, Syed Hasan Tahir, Gerald J. Wallweber, Hrair Kirakossian, Tracy J. Matray, Vincent S. Hernandez
  • Drug selection for breast cancer therapy using antibody-based arrays
    Patent number: 9274116
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 1, 2016
    Assignee: NESTEC S.A.
    Inventors: Sharat Singh, Jeanne Harvey, Phillip Kim, Xinjun Liu, Limin Liu, Robert Barham, Bruce Neri
  • DRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPY
    Publication number: 20160032403
    Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
    Type: Application
    Filed: July 29, 2015
    Publication date: February 4, 2016
    Applicant: NESEC S.A,
    Inventors: Sharat Singh, Phillip Kim, Steven Lockton
  • Drug selection for lung cancer therapy using antibody-based arrays
    Patent number: 9250243
    Abstract: The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: February 2, 2016
    Assignee: NESTEC S.A.
    Inventors: Sharat Singh, Jeanne Harvey
  • METHODS OF SELECTING COMBINATION THERAPY FOR COLORECTAL CANCER PATIENTS
    Publication number: 20160025730
    Abstract: The present invention provides methods for selecting a subject as suitable for combination therapy with EGFR and HER2 inhibitors. The present invention also provides methods for predicting whether a subject will benefit from the combination therapy. In some embodiments, the present invention provides methods for determining whether to administer a combination therapy in a subject receiving EGFR inhibitor therapy. In other embodiments, the present invention provides methods for monitoring a subject on EGFR inhibitor therapy to determine whether to administer a combination therapy of EGFR and HER2 inhibitors. The present invention is particularly useful to facilitate the design of personalized therapies for colorectal cancer patients with EGFR inhibitor sensitivity.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 28, 2016
    Applicant: NESTEC S.A.
    Inventors: Phillip KIM, Xinjun LIU, Sharat SINGH